Dr. Leslie Hudson to become CEO and President of DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. announced that Dr. Leslie Hudson will become the company's chief executive officer and president. Dr. Hudson is expected to start by the end of July 2005. DOV's co-founder, Dr. Arnold Lippa, currently chairman, CEO and president, will continue to serve as chairman of the board.
Dr. Hudson brings over 15 years of corporate pharmaceutical experience to DOV, having served in senior level leadership positions at Pharmacia Corporation and Glaxo Inc. Dr. Hudson was also COO at Repligen Corporation, a biopharmaceutical company. In his eight years at Pharmacia, Dr. Hudson was senior vice president of research and exploratory development and then group vice president and general manager for the ophthalmology business. Dr. Hudson established strong business partnerships with other biotech firms while at Glaxo and Pharmacia.
After the Pharmacia-Pfizer merger, Dr. Hudson became vice provost, office of strategic initiatives, at the University of Pennsylvania where he managed the commercialization of discoveries from research grants and contracts worth over $750 million per annum, headed corporate R&D relationships, oversaw government economic development programs and established the entrepreneurship business unit. He serves as an executive committee member of the board of directors at the Pennsylvania Biotech Association and the Philadelphia Science Center and on the board of directors of Hooper Holmes, Inc.
Prior to joining industry, Dr. Hudson spent nearly nine years at St. George's Hospital Medical School in London, where he earned the distinction of full professor of immunology and chairman of the department. He received a Ph.D from the department of immunology, Middlesex Hospital Medical School, University of London in 1975, was elected associate of the Royal College of Science and received his bachelor of science degree, summa cum laude, from the Imperial College of Science, Technology and Medicine, University of London, in 1968.
Other news from the department people
